Bernstein analyst Jeffrey Walch maintained a ‘hold’ rating on Incyte on Tuesday, setting a target price of $104.00. The company’s stock closed at $123.89 on Tuesday.
Walch covers the healthcare sector, with key stocks under tracking including Neurocrine, Alnylam Pharma, and Vertex Pharmaceuticals. According to TipRanks data, the average return on the recommended stocks by Walch is 4.8%, with a success rate of 58.33%.
Incyte Currently, analysts unanimously rate it as 'moderate buy', with a consensus target price of $130.79, representing a potential upside of 5.57% from the current level. RBC Capital also maintained a 'hold' rating for the stock in a report released on September 22, with a target price of $109.00.
According to the latest financial report for the quarter ending June 30th as per Incyte, the company's revenue for that quarter was 1.67 billion US dollars, with a net profit of 585.61 million US dollars. In contrast, during the same period last year, the company's revenue was 1.22 billion US dollars, and the net profit was 405 million US dollars.
Based on recent insider trading activities involving 92 insiders within the company, the sentiment among these insiders regarding the stock is negative. This indicates that there has been an increase in the number of insiders selling INCY shares over the past quarter compared to earlier this year. Earlier this month, INCY President Pablo Cagnoni sold 23,218 shares, with a total value of $2,797,629.15.











